Medsir

This study tests whether a chemotherapy-free combination of targeted drugs (trastuzumab, pertuzumab, and T-DM1) can effectively treat HER2-positive early breast cancer. About 393 adults with early-stage disease will receive these drugs before and after surgery. The goal is to see…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (carboplatin and paclitaxel) can completely eliminate tumors in people with stage I triple-negative breast cancer before surgery. About 31 participants with small, lymph-node-negative tu…

This study tests a two-step treatment for people with HER2-positive breast cancer that has spread or cannot be removed. First, patients receive a strong drug called trastuzumab deruxtecan. Then, they switch to a maintenance combination of two other drugs (trastuzumab and pertuzum…

This study tests a drug called Trastuzumab-Deruxtecan (T-DXd) in 28 people with HER2-low breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors and control the cancer. Participants receive the drug intravenously, and doctors monitor tum…

This study tests a new drug (MEN1611) combined with chemotherapy (eribulin) in people with advanced breast cancer that has specific genetic changes (PIK3CA/PTEN). The goal is to see if the combination can shrink tumors or stop them from growing. The trial includes 14 adults whose…

This study aimed to test a combination of three drugs (zimberelimab, domvanalimab, and sacituzumab govitecan) as a first treatment for people with a specific type of advanced breast cancer (PD-L1 positive triple-negative breast cancer). The goal was to see if the combination coul…

This study tests a new combination of two drugs (Debio 0123 and sacituzumab govitecan) in people with advanced breast cancer that has not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors. The study includes two types of b…